SEC Form 4 · accession 0001209191-17-040615
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven B Ruchefsky
Director
Period of report
Jun 14, 2017
Accepted (ET)
Jun 16, 2017 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 14, 2017 | S | 20,000 | $89.4787 | D | 205,426 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person's sale of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,400 shares, with the reporting person's purchase of 1,400 shares of the Issuer's common stock at a price of $69.50 per share on May 9, 2017. The reporting person has agreed to pay to the Issuer, upon settlement of the trade, $28,945 representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.25 to $90.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.